U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C18H19N3O3S
Molecular Weight 357.427
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ROSIGLITAZONE

SMILES

CN(CCOC1=CC=C(CC2SC(=O)NC2=O)C=C1)C3=CC=CC=N3

InChI

InChIKey=YASAKCUCGLMORW-UHFFFAOYSA-N
InChI=1S/C18H19N3O3S/c1-21(16-4-2-3-9-19-16)10-11-24-14-7-5-13(6-8-14)12-15-17(22)20-18(23)25-15/h2-9,15H,10-12H2,1H3,(H,20,22,23)

HIDE SMILES / InChI
Molecular Formula C18H19N3O3S
Molecular Weight 357.427
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description
Curator's Comment: description was created based on several sources, including: https://www.drugs.com/mtm/rosiglitazone.html http://www.rxlist.com/avandia-drug.htm http://www.wikidoc.org/index.php/Rosiglitazone

Rosiglitazone acts as a highly selective and potent agonist at peroxisome proliferator activated receptors (PPAR) in target tissues for insulin action such as adipose tissue, skeletal muscle, and liver. It is FDA approved for the treatment of as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Inhibitors of CYP2C8 (e.g., gemfibrozil) may increase rosiglitazone levels; inducers of CYP2C8 (e.g., rifampin) may decrease rosiglitazone levels. Common adverse reactions include edema, weight gain, and headache.

CNS Activity

Originator

Approval Year

1999
159
Targets

Targets

Primary TargetPharmacologyConditionPotency
Agonist
2662
 40.0 nM [Kd]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8360
AVANDIA

Approved Use

After consultation with a healthcare professional who has considered and advised the patient of the risks and benefits of rosiglitazone, AVANDAMET® is indicated as an adjunct to diet and exercise to improve glycemic control when treatment with both rosiglitazone and metformin is appropriate in adults with type 2 diabetes mellitus who either are: already taking rosiglitazone, or not already taking rosiglitazone and unable to achieve glycemic control on other diabetes medications and, in consultation with their healthcare provider, have decided not to take pioglitazone (ACTOS®) or pioglitazone-containing products (ACTOPLUS MET®, ACTOPLUS MET XR®, DUETACT®) for medical reasons. Other Important Limitations of Use: Due to its mechanism of action, rosiglitazone is active only in the presence of endogenous insulin. Therefore, AVANDAMET should not be used in patients with type 1 diabetes. Coadministration of AVANDAMET with insulin is not recommended [see Warnings and Precautions (5.2, 5.3)

Launch Date

9.2759038E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
432 ng/mL
DRUG LABEL
https://www.fda.gov/media/75754/download
8 mg single, oral
dose: 8 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ROSIGLITAZONE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: FED
598 ng/mL
DRUG LABEL
https://www.fda.gov/media/75754/download
8 mg single, oral
dose: 8 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ROSIGLITAZONE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
2890 ng × h/mL
DRUG LABEL
https://www.fda.gov/media/75754/download
8 mg single, oral
dose: 8 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ROSIGLITAZONE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: FED
2971 ng × h/mL
DRUG LABEL
https://www.fda.gov/media/75754/download
8 mg single, oral
dose: 8 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ROSIGLITAZONE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
3.59 h
DRUG LABEL
https://www.fda.gov/media/75754/download
8 mg single, oral
dose: 8 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ROSIGLITAZONE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: FED
3.37 h
DRUG LABEL
https://www.fda.gov/media/75754/download
8 mg single, oral
dose: 8 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ROSIGLITAZONE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
8 mg 1 times / day multiple, oral
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/18503774
Page: p.105
unhealthy, 53.1
n = 32
Health Status: unhealthy
Condition: Nonalcoholic steatohepatitis
Age Group: 53.1
Sex: M+F
Population Size: 32
Sources:
https://pubmed.ncbi.nlm.nih.gov/18503774
Page: p.105
DLT: Headache, Malaise...
Disc. AE: Pain in leg...
Dose limiting toxicities:
Headache (3.1%)
Malaise (3.1%)
Oedema legs (9.4%)
AEs leading to
discontinuation/dose reduction:
Pain in leg (3.1%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/18503774
Page: p.105
20 mg single, oral
Overdose
Dose: 20 mg
Route: oral
Route: single
Dose: 20 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/25390127
Page: p.73,74
unhealthy, 60
n = 1
Health Status: unhealthy
Condition: Type 2 diabetes mellitus
Age Group: 60
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/25390127
Page: p.73,74
Disc. AE: Macular edema...
AEs leading to
discontinuation/dose reduction:
Macular edema
Sources:
https://pubmed.ncbi.nlm.nih.gov/25390127
Page: p.73,74
8 mg 1 times / day multiple, oral
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021071s031lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Type 2 diabetes mellitus
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021071s031lbl.pdf
Page: p.1
Disc. AE: Congestive heart failure, Myocardial ischemia...
AEs leading to
discontinuation/dose reduction:
Congestive heart failure
Myocardial ischemia (2%)
Fluid retention
Edema
Weight gain
Anemia
Macular edema
Fracture bone
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021071s031lbl.pdf
Page: p.1
AEs

AEs

AESignificanceDosePopulation
Headache 3.1%
DLT
8 mg 1 times / day multiple, oral
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/18503774
Page: p.105
unhealthy, 53.1
n = 32
Health Status: unhealthy
Condition: Nonalcoholic steatohepatitis
Age Group: 53.1
Sex: M+F
Population Size: 32
Sources:
https://pubmed.ncbi.nlm.nih.gov/18503774
Page: p.105
Malaise 3.1%
DLT
8 mg 1 times / day multiple, oral
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/18503774
Page: p.105
unhealthy, 53.1
n = 32
Health Status: unhealthy
Condition: Nonalcoholic steatohepatitis
Age Group: 53.1
Sex: M+F
Population Size: 32
Sources:
https://pubmed.ncbi.nlm.nih.gov/18503774
Page: p.105
Pain in leg 3.1%
Disc. AE
8 mg 1 times / day multiple, oral
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/18503774
Page: p.105
unhealthy, 53.1
n = 32
Health Status: unhealthy
Condition: Nonalcoholic steatohepatitis
Age Group: 53.1
Sex: M+F
Population Size: 32
Sources:
https://pubmed.ncbi.nlm.nih.gov/18503774
Page: p.105
Oedema legs 9.4%
DLT
8 mg 1 times / day multiple, oral
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/18503774
Page: p.105
unhealthy, 53.1
n = 32
Health Status: unhealthy
Condition: Nonalcoholic steatohepatitis
Age Group: 53.1
Sex: M+F
Population Size: 32
Sources:
https://pubmed.ncbi.nlm.nih.gov/18503774
Page: p.105
Macular edema Disc. AE
20 mg single, oral
Overdose
Dose: 20 mg
Route: oral
Route: single
Dose: 20 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/25390127
Page: p.73,74
unhealthy, 60
n = 1
Health Status: unhealthy
Condition: Type 2 diabetes mellitus
Age Group: 60
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/25390127
Page: p.73,74
Myocardial ischemia 2%
Disc. AE
8 mg 1 times / day multiple, oral
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021071s031lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Type 2 diabetes mellitus
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021071s031lbl.pdf
Page: p.1
Anemia Disc. AE
8 mg 1 times / day multiple, oral
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021071s031lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Type 2 diabetes mellitus
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021071s031lbl.pdf
Page: p.1
Congestive heart failure Disc. AE
8 mg 1 times / day multiple, oral
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021071s031lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Type 2 diabetes mellitus
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021071s031lbl.pdf
Page: p.1
Edema Disc. AE
8 mg 1 times / day multiple, oral
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021071s031lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Type 2 diabetes mellitus
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021071s031lbl.pdf
Page: p.1
Fluid retention Disc. AE
8 mg 1 times / day multiple, oral
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021071s031lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Type 2 diabetes mellitus
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021071s031lbl.pdf
Page: p.1
Fracture bone Disc. AE
8 mg 1 times / day multiple, oral
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021071s031lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Type 2 diabetes mellitus
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021071s031lbl.pdf
Page: p.1
Macular edema Disc. AE
8 mg 1 times / day multiple, oral
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021071s031lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Type 2 diabetes mellitus
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021071s031lbl.pdf
Page: p.1
Weight gain Disc. AE
8 mg 1 times / day multiple, oral
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021071s031lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Type 2 diabetes mellitus
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021071s031lbl.pdf
Page: p.1
PubMed

PubMed

TitleDatePubMed
Expression of phosphoenolpyruvate carboxykinase gene in human adipose tissue: induction by rosiglitazone and genetic analyses of the adipocyte-specific region of the promoter in type 2 diabetes.
2003 Dec
Reduction in the evolution of murine type II collagen-induced arthritis by treatment with rosiglitazone, a ligand of the peroxisome proliferator-activated receptor gamma.
2003 Dec
Resistin and type 2 diabetes: regulation of resistin expression by insulin and rosiglitazone and the effects of recombinant resistin on lipid and glucose metabolism in human differentiated adipocytes.
2003 Dec
Rosiglitazone produces insulin sensitisation by increasing expression of the insulin receptor and its tyrosine kinase activity in brown adipocytes.
2003 Dec
PPARgamma ligands induce prostaglandin production in vascular smooth muscle cells: indomethacin acts as a peroxisome proliferator-activated receptor-gamma antagonist.
2003 Oct
Induction of apoptosis by mono(2-ethylhexyl)phthalate (MEHP) in U937 cells.
2003 Oct 15
A phase II trial with rosiglitazone in liposarcoma patients.
2003 Oct 20
Rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2, ligands of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), reduce ischaemia/reperfusion injury of the gut.
2003 Sep
Rosiglitazone inhibits the insulin-mediated increase in PAI-1 secretion in human abdominal subcutaneous adipocytes.
2003 Sep
Cinnamic acid based thiazolidinediones inhibit human P450c17 and 3beta-hydroxysteroid dehydrogenase and improve insulin sensitivity independent of PPARgamma agonist activity.
2004 Apr
Rosiglitazone prevents the impairment of human islet function induced by fatty acids: evidence for a role of PPARgamma2 in the modulation of insulin secretion.
2004 Apr
Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes.
2004 Aug
The PPARgamma ligands PGJ2 and rosiglitazone show a differential ability to inhibit proliferation and to induce apoptosis and differentiation of human glioblastoma cell lines.
2004 Aug
Decreased expression of peroxisome proliferator activated receptor gamma in cftr-/- mice.
2004 Aug
[Anti-hypertensive effect of rosiglitazone in non-diabetic essential hypertension].
2004 Dec
Effect of peroxisome proliferator-activated receptor gamma agonist, rosiglitazone, on dedifferentiated thyroid cancers.
2004 Dec
A yeast two-hybrid technology-based system for the discovery of PPARgamma agonist and antagonist.
2004 Dec 15
Bone is a target for the antidiabetic compound rosiglitazone.
2004 Jan
Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-gamma, reduces acute inflammation.
2004 Jan 1
Reduction of intracellular cholesterol accumulation in THP-1 macrophages by a combination of rosiglitazone and atorvastatin.
2004 Jul 1
Evidence for a potent antiinflammatory effect of rosiglitazone.
2004 Jun
Rosiglitazone induction of Insig-1 in white adipose tissue reveals a novel interplay of peroxisome proliferator-activated receptor gamma and sterol regulatory element-binding protein in the regulation of adipogenesis.
2004 Jun 4
PPAR(gamma) agonist rosiglitazone improves vascular function and lowers blood pressure in hypertensive transgenic mice.
2004 Mar
Rosiglitazone facilitates angiogenic progenitor cell differentiation toward endothelial lineage: a new paradigm in glitazone pleiotropy.
2004 Mar 23
Rosiglitazone improves insulin sensitivity, glucose tolerance and ambulatory blood pressure in subjects with impaired glucose tolerance.
2004 May
Transactivation of the PPAR-responsive enhancer module in chemopreventive glutathione S-transferase gene by the peroxisome proliferator-activated receptor-gamma and retinoid X receptor heterodimer.
2004 May 15
Mitochondrial remodeling in adipose tissue associated with obesity and treatment with rosiglitazone.
2004 Nov
Hepatic lipase mRNA, protein, and plasma enzyme activity is increased in the insulin-resistant, fructose-fed Syrian golden hamster and is partially normalized by the insulin sensitizer rosiglitazone.
2004 Nov
Rosiglitazone upregulates caveolin-1 expression in THP-1 cells through a PPAR-dependent mechanism.
2004 Nov
Chronic heart failure-related interventions after starting rosiglitazone in patients receiving insulin.
2004 Oct
Peroxisome proliferator-activated receptor and farnesoid X receptor ligands differentially regulate sebaceous differentiation in human sebaceous gland organ cultures in vitro.
2004 Oct
Comparison of the effects of pioglitazone and rosiglitazone on macrophage foam cell formation.
2004 Oct 22
Rosiglitazone treatment improves insulin regulation and dyslipidemia in type 2 diabetic cynomolgus monkeys.
2004 Sep
The antidiabetic agent rosiglitazone upregulates SERCA2 and enhances TNF-alpha- and LPS-induced NF-kappaB-dependent transcription and TNF-alpha-induced IL-6 secretion in ventricular myocytes.
2005
Rosiglitazone, PPAR-gamma receptor ligand, decreases the viability of rat prolactin-secreting pituitary tumor cells in vitro.
2005 Feb
Effect of rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2 on bleomycin-induced lung injury.
2005 Feb
Chaperone proteins involved in troglitazone-induced toxicity in human hepatoma cell lines.
2005 Feb
The effects of rosiglitazone on fatty acid and triglyceride metabolism in type 2 diabetes.
2005 Jan
Enhanced insulin-stimulated glycogen synthesis in response to insulin, metformin or rosiglitazone is associated with increased mRNA expression of GLUT4 and peroxisomal proliferator activator receptor gamma co-activator 1.
2005 Jun
Rosiglitazone induces interleukin-1 receptor antagonist in interleukin-1beta-stimulated rat synovial fibroblasts via a peroxisome proliferator-activated receptor beta/delta-dependent mechanism.
2005 Mar
The peroxisome proliferator-activated receptor gamma ligand rosiglitazone delays the onset of inflammatory bowel disease in mice with interleukin 10 deficiency.
2005 Mar
Thiazolidinediones inhibit proliferation of microvascular and macrovascular cells by a PPARgamma-independent mechanism.
2005 Mar
Development of a complex scintillation proximity assay for high-throughput screening of PPARgamma modulators.
2005 Mar
Comparison of pioglitazone with other antidiabetic drugs for associated incidence of liver failure: no evidence of increased risk of liver failure with pioglitazone.
2005 Mar
Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation.
2005 Mar
The influence of adiponectin gene polymorphism on the rosiglitazone response in patients with type 2 diabetes.
2005 May
Effects of metformin and rosiglitazone treatment on insulin signaling and glucose uptake in patients with newly diagnosed type 2 diabetes: a randomized controlled study.
2005 May
Rosiglitazone increases indexes of stearoyl-CoA desaturase activity in humans: link to insulin sensitization and the role of dominant-negative mutation in peroxisome proliferator-activated receptor-gamma.
2005 May
Mechanism of the anti-inflammatory effect of thiazolidinediones: relationship with the glucocorticoid pathway.
2005 May
Trialkyltin compounds bind retinoid X receptor to alter human placental endocrine functions.
2005 Oct
Patents

Patents

06515132
8
JP2002543077A
8
JP2004536047A
24
JP2008195625A
8
JP2011252007A
8
JP4365554B2
22
JP4741458B2
8

Sample Use Guides

In Vivo Use Guide
Start at 4 mg daily in single or divided doses; do not exceed 8 mg daily.
Route of Administration: Oral
In Vitro Use Guide
Rosiglitazone treatment (5 uM) prevents NO and prostacyclin overproduction by inhibiting microparticles-induced iNOS and COX-2 expression.
Substance Class Chemical
Created
by admin
on Wed Jul 05 23:45:24 UTC 2023
Edited
by admin
on Wed Jul 05 23:45:24 UTC 2023
Record UNII
05V02F2KDG
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ROSIGLITAZONE
EMA EPAR   HSDB   INN   MART.   MI   VANDF   WHO-DD  
INN  
Official Name English
ROSIGLIZOLE
Brand Name English
BRL-49653
Code English
NSC-758698
Code English
ROSIGLITAZONE [MI]
Common Name English
rosiglitazone [INN]
Common Name English
ROSIGLITAZONE [EMA EPAR]
Common Name English
REZULT
Brand Name English
TDZ-01
Code English
ROSIGLITAZONE [VANDF]
Common Name English
2,4-THIAZOLIDINEDIONE, 5-((4-(2-(METHYL-2-PYRIDINYLAMINO)ETHOXY)PHENYL)METHYL)-
Systematic Name English
ROSIGLITAZONE [MART.]
Common Name English
ROSIGLITAZONE [IARC]
Common Name English
ROSVEL
Brand Name English
GAUDIL
Brand Name English
5-((4-(2-(METHYL-2-PYRIDINYLAMINO)ETHOXY)PHENYL)METHYL)-2,4-THIAZOLIDINEDIONE
Systematic Name English
ROSIGLITAZONE [HSDB]
Common Name English
Rosiglitazone [WHO-DD]
Common Name English
5-(4-(2-(N-METHYL-N-(2-PYRIDINYL)AMINO)ETHOXY)BENZYL)-2,4-THIAZOLIDINEDIONE
Systematic Name English
Classification Tree Code System Code
NCI_THESAURUS C98241
Created by admin on Wed Jul 05 23:45:24 UTC 2023 , Edited by admin on Wed Jul 05 23:45:24 UTC 2023
NDF-RT N0000011272
Created by admin on Wed Jul 05 23:45:24 UTC 2023 , Edited by admin on Wed Jul 05 23:45:24 UTC 2023
WHO-ATC A10BD03
Created by admin on Wed Jul 05 23:45:24 UTC 2023 , Edited by admin on Wed Jul 05 23:45:24 UTC 2023
LIVERTOX NBK548114
Created by admin on Wed Jul 05 23:45:24 UTC 2023 , Edited by admin on Wed Jul 05 23:45:24 UTC 2023
NDF-RT N0000180190
Created by admin on Wed Jul 05 23:45:24 UTC 2023 , Edited by admin on Wed Jul 05 23:45:24 UTC 2023
WHO-ATC A10BD04
Created by admin on Wed Jul 05 23:45:24 UTC 2023 , Edited by admin on Wed Jul 05 23:45:24 UTC 2023
WHO-VATC QA10BG02
Created by admin on Wed Jul 05 23:45:24 UTC 2023 , Edited by admin on Wed Jul 05 23:45:24 UTC 2023
NDF-RT N0000175374
Created by admin on Wed Jul 05 23:45:24 UTC 2023 , Edited by admin on Wed Jul 05 23:45:24 UTC 2023
NCI_THESAURUS C1934
Created by admin on Wed Jul 05 23:45:24 UTC 2023 , Edited by admin on Wed Jul 05 23:45:24 UTC 2023
WHO-VATC QA10BD04
Created by admin on Wed Jul 05 23:45:24 UTC 2023 , Edited by admin on Wed Jul 05 23:45:24 UTC 2023
WHO-ATC A10BG02
Created by admin on Wed Jul 05 23:45:24 UTC 2023 , Edited by admin on Wed Jul 05 23:45:24 UTC 2023
NDF-RT N0000170119
Created by admin on Wed Jul 05 23:45:24 UTC 2023 , Edited by admin on Wed Jul 05 23:45:24 UTC 2023
NDF-RT N0000011272
Created by admin on Wed Jul 05 23:45:24 UTC 2023 , Edited by admin on Wed Jul 05 23:45:24 UTC 2023
WHO-VATC QA10BD03
Created by admin on Wed Jul 05 23:45:24 UTC 2023 , Edited by admin on Wed Jul 05 23:45:24 UTC 2023
NDF-RT N0000180186
Created by admin on Wed Jul 05 23:45:24 UTC 2023 , Edited by admin on Wed Jul 05 23:45:24 UTC 2023
NDF-RT N0000170119
Created by admin on Wed Jul 05 23:45:24 UTC 2023 , Edited by admin on Wed Jul 05 23:45:24 UTC 2023
NDF-RT N0000011272
Created by admin on Wed Jul 05 23:45:24 UTC 2023 , Edited by admin on Wed Jul 05 23:45:24 UTC 2023
Code System Code Type Description
SMS_ID
100000089168
Created by admin on Wed Jul 05 23:45:24 UTC 2023 , Edited by admin on Wed Jul 05 23:45:24 UTC 2023
PRIMARY
EVMPD
SUB10388MIG
Created by admin on Wed Jul 05 23:45:24 UTC 2023 , Edited by admin on Wed Jul 05 23:45:24 UTC 2023
PRIMARY
DRUG CENTRAL
2405
Created by admin on Wed Jul 05 23:45:24 UTC 2023 , Edited by admin on Wed Jul 05 23:45:24 UTC 2023
PRIMARY
INN
7662
Created by admin on Wed Jul 05 23:45:24 UTC 2023 , Edited by admin on Wed Jul 05 23:45:24 UTC 2023
PRIMARY
PUBCHEM
77999
Created by admin on Wed Jul 05 23:45:24 UTC 2023 , Edited by admin on Wed Jul 05 23:45:24 UTC 2023
PRIMARY
HSDB
7555
Created by admin on Wed Jul 05 23:45:24 UTC 2023 , Edited by admin on Wed Jul 05 23:45:24 UTC 2023
PRIMARY
DRUG BANK
DB00412
Created by admin on Wed Jul 05 23:45:24 UTC 2023 , Edited by admin on Wed Jul 05 23:45:24 UTC 2023
PRIMARY
NSC
758698
Created by admin on Wed Jul 05 23:45:24 UTC 2023 , Edited by admin on Wed Jul 05 23:45:24 UTC 2023
PRIMARY
LACTMED
Rosiglitazone
Created by admin on Wed Jul 05 23:45:24 UTC 2023 , Edited by admin on Wed Jul 05 23:45:24 UTC 2023
PRIMARY
WIKIPEDIA
ROSIGLITAZONE
Created by admin on Wed Jul 05 23:45:24 UTC 2023 , Edited by admin on Wed Jul 05 23:45:24 UTC 2023
PRIMARY
IUPHAR
1056
Created by admin on Wed Jul 05 23:45:24 UTC 2023 , Edited by admin on Wed Jul 05 23:45:24 UTC 2023
PRIMARY
DAILYMED
05V02F2KDG
Created by admin on Wed Jul 05 23:45:24 UTC 2023 , Edited by admin on Wed Jul 05 23:45:24 UTC 2023
PRIMARY
CHEBI
50122
Created by admin on Wed Jul 05 23:45:24 UTC 2023 , Edited by admin on Wed Jul 05 23:45:24 UTC 2023
PRIMARY
MESH
C089730
Created by admin on Wed Jul 05 23:45:24 UTC 2023 , Edited by admin on Wed Jul 05 23:45:24 UTC 2023
PRIMARY
NCI_THESAURUS
C62076
Created by admin on Wed Jul 05 23:45:24 UTC 2023 , Edited by admin on Wed Jul 05 23:45:24 UTC 2023
PRIMARY
EPA CompTox
DTXSID7037131
Created by admin on Wed Jul 05 23:45:24 UTC 2023 , Edited by admin on Wed Jul 05 23:45:24 UTC 2023
PRIMARY
MERCK INDEX
M9666
Created by admin on Wed Jul 05 23:45:24 UTC 2023 , Edited by admin on Wed Jul 05 23:45:24 UTC 2023
PRIMARY Merck Index
CAS
122320-73-4
Created by admin on Wed Jul 05 23:45:24 UTC 2023 , Edited by admin on Wed Jul 05 23:45:24 UTC 2023
PRIMARY
ChEMBL
CHEMBL121
Created by admin on Wed Jul 05 23:45:24 UTC 2023 , Edited by admin on Wed Jul 05 23:45:24 UTC 2023
PRIMARY
FDA UNII
05V02F2KDG
Created by admin on Wed Jul 05 23:45:24 UTC 2023 , Edited by admin on Wed Jul 05 23:45:24 UTC 2023
PRIMARY
RXCUI
84108
Created by admin on Wed Jul 05 23:45:24 UTC 2023 , Edited by admin on Wed Jul 05 23:45:24 UTC 2023
PRIMARY RxNorm
Related Record Type Details
CYTOCHROME P450 2C8
METABOLIC ENZYME -> SUBSTRATE
PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA
TARGET -> INHIBITOR
Binding Assay
IC50
Structure of ROSIGLITAZONE POTASSIUM
SALT/SOLVATE -> PARENT
OATP-B
TRANSPORTER -> INHIBITOR
SUBSTRATE USED: Bromsulphthalein (BSP)
Structure of ROSIGLITAZONE MALEATE
SALT/SOLVATE -> PARENT
Structure of ROSIGLITAZONE, (S)-
ENANTIOMER -> RACEMATE
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
BINDING
Structure of Rosiglitazone tartrate
SALT/SOLVATE -> PARENT
Structure of ROSIGLITAZONE SODIUM
SALT/SOLVATE -> PARENT
OATP-8
TRANSPORTER -> INHIBITOR
Structure of ROSIGLITAZONE MALEATE
SALT/SOLVATE -> PARENT
Structure of ROSIGLITAZONE HYDROCHLORIDE
SALT/SOLVATE -> PARENT
Structure of ROSIGLITAZONE FUMARATE
SALT/SOLVATE -> PARENT
OATP1B1
TRANSPORTER -> INHIBITOR
Structure of ROSIGLITAZONE CHOLINATE
SALT/SOLVATE -> PARENT
Structure of ROSIGLITAZONE, (R)-
ENANTIOMER -> RACEMATE
OCT-1
TRANSPORTER -> INHIBITOR
Related Record Type Details
Structure of N-DESMETHYL-O-HYDROXY ROSIGLITAZONE
METABOLITE INACTIVE -> PARENT
MINOR
Structure of P-HYDROXY ROSIGLITAZONE
METABOLITE ACTIVE -> PARENT
MAJOR
Related Record Type Details
Structure of ROSIGLITAZONE
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966